Current management of Behçet syndrome
Authors:
- 27 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
Abstract
Purpose of review: To summarize the most clinically relevant recent advances in the treatment of Behçet syndrome (BS), with emphasis on the updated 2025 EULAR recommendations and emerging evidence across different organ manifestations. Recent findings: The updated EULAR recommendations support earlier use of monoclonal TNF inhibitors (TNFi), particularly in severe ocular, vascular, and neurologic involvement, and favor their continued use for maintenance in selected major-organ disease. Recent randomized and comparative studies provide further support for TNFi in Behçet uveitis and vascular involvement. Newer agents, including PDE-4 inhibitors and JAK inhibitors (JAKi), have shown promising efficacy in mucocutaneous, gastrointestinal, ocular, vascular, and neurologic disease, although most evidence for JAKi remains derived from small uncontrolled studies. Ustekinumab has also shown encouraging results in refractory intestinal BS. The role of anticoagulation in vascular BS remains uncertain. Summary: Management of BS is increasingly organ- and risk-adapted, with earlier use of effective targeted therapies in patients at risk of irreversible damage. Despite encouraging results with several newer agents, comparative and high-quality evidence remains limited, highlighting the need for adequately powered studies with organ-specific outcomes.Keywords
This publication has 29 references indexed in Scilit:
- Comparative efficacy and safety of tofacitinib versus adalimumab in patients with Behçet’s uveitis: a real-world retrospective studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2026
- Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendationsEULAR Rheumatology Open, 2026
- EULAR recommendations for the management of Behçet’s syndrome: 2025 updateAnnals of the Rheumatic Diseases, 2026
- Management of mucocutaneous and joint involvement of Behçet’s syndrome: a systematic literature review informing the 2025 update of the EULAR recommendationsEULAR Rheumatology Open, 2026
- Efficacy and safety of mufemilast in patients with Behçet’s syndrome: a phase 2 randomised clinical trialAnnals of the Rheumatic Diseases, 2026
- The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Behçet's syndrome: A systematic review and meta-analysisAutoimmunity Reviews, 2025
- Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective studyClinical Rheumatology, 2024
- Infliximab for vascular involvement in Behçet's syndromeClinical Immunology, 2023
- Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trialJournal of the American Academy of Dermatology, 2022
- Long‐Term Outcome of Ustekinumab Therapy for Behçet's DiseaseArthritis & Rheumatology, 2019